[1]
|
P. Loiseau, P. Henry, P. Jallon and M. Legroux, “Iatrogenic Myoclonic Encephalopathies Caused by Bismuth Salts,” Journal of the Neurological Sciences, Vol. 27, No. 2, 1976, pp. 133-143.
doi:10.1016/0022-510X(76)90056-3
|
[2]
|
M. Teepker, H. M. Hamer, S. Knake, O. Bandmann, W. H. Oertel and F. Rosenow, “Myoclonic Encephalopathy Caused by Chronic Bismuth Abuse,” Epileptic Disorders, Vol. 4, No. 4, 2002, pp. 229-233.
|
[3]
|
J. C. Hutson, “Effects of Bismuth Citrate on the Viability and Function of Leydig Cells and Testicular Macrophages,” Journal of Applied Toxicology, Vol. 25, No. 3, 2005, pp. 234-238. doi:10.1002/jat.1060
|
[4]
|
Micromedex, “Healthcare Series,” Thomson Reuters (Healthcare) Inc., Greenwood Village, Accessed 21 December 2011.
|
[5]
|
P. M. Le-Quesne, “Toxic Substances and the Nervous System: The Role of Clinical Observation,” Journal of Neurology, Neurosurgery, and Psychiatry, Vol. 44, No. 1, 1981, pp. 1-8. doi:10.1136/jnnp.44.1.1
|
[6]
|
I. Zerr, M. Pocchiari, S. Collins, et al., “Analysis of EEG and CSF 14-3-3 Proteins as Aids to the Diagnosis of Creutzfeldt-Jakob Disease,” Neurology, Vol. 55, No. 6, 2000, pp. 811-815.
|
[7]
|
I. Kothbauer-Margreiter, M. Sturzenegger, J. Komor, R. Baumgartner and C. W. Hess, “Encephalopathy Associated with Hashimoto Thyroiditis: Diagnosis and Treatment,” Journal of Neurology, Vol. 243, No. 8, 1996, pp. 585-593. doi:10.1007/BF00900946
|
[8]
|
F. Ferracci, G. Bertiato and G. Moretto, “Hashimoto’s Encephalopathy: Epidemiologic Data and Pathogenetic Considerations,” Journal of the Neurological Sciences, Vol. 217, No. 2, 2004, pp. 165-168.
doi:10.1016/j.jns.2003.09.007
|
[9]
|
M. Borg, “Symptomatic Myoclonus,” Neurophysiologie Clinique, Vol. 36, No. 5-6, 2006, pp. 309-318.
doi:10.1016/j.neucli.2006.12.006
|
[10]
|
C. D. Marsden, A. E. Harding, J. A. Obeso and C. S. Lu, “Progressive Myoclonic Ataxia (the Ramsay Hunt Syndrome),” Archives of Neurology, Vol. 47, No. 10, 1990, pp. 1121-1125.
doi:10.1001/archneur.1990.00530100091019
|
[11]
|
P. Birmes, D. Coppin, L. Schmitt and D. Lauque, “Serotonin Syndrome: A Brief Review,” Canadian Medical Association Journal, Vol. 168, No. 11, 2003, pp. 1439-1442.
|
[12]
|
A. C. Ford, P. Malfertheiner, M. Giguere, J. Santana, M. Khan and P. Moayyedi, “Adverse Events with Bismuth Salts for Helicobacter Pylori Eradication: Systematic Review and Meta-Analysis,” World Journal of Gastroenterology, Vol. 14, No. 48, 2008, pp. 7361-7370.
doi:10.3748/wjg.14.7361
|
[13]
|
M. D. Ioffreda, C. A. Gordon, D. R. Adams, S. J. Naides and J. J. Miller, “Black Tongue,” Archives of Dermatology, Vol. 137, No. 7, 2001, pp. 968-969.
|
[14]
|
M. F. Gordon, R. I. Abrams, D. B. Rubin, W. B. Barr and D. D. Correa, “Bismuth Subsalicylate Toxicity as a Cause of Prolonged Encephalopathy with Myoclonus,” Movement Disorders, Vol. 10, No. 2, 1995, pp. 220-222.
doi:10.1002/mds.870100215
|
[15]
|
H. Ovaska, D. M. Wood, I. House, P. I. Dargan, A. L. Jones and S. Murray, “Severe Iatrogenic Bismuth Poisoning with BIsmuth Iodoform Paraffin Paste Treated with DMPS Chelation,” Clinical Toxicology, Vol. 46, No. 9, 2008, pp. 855-857. doi:10.1080/15563650801953182
|